-

Alexion to Present at the Virtual Bank of America Securities 2020 Healthcare Conference

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the Bank of America Securities 2020 Healthcare Conference, taking place virtually on Tuesday, May 12th, 2020 at 1:00 p.m. ET.

An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.alexion.com. An archived version of the remarks will also be available through the Company’s website for a limited time following the conference.

[ALXN-G]

Contacts

Investors
Chris Stevo
Head of Investor Relations
(857) 338-9309

Industry:

Alexion Pharmaceuticals

NASDAQ:ALXN
Release Summary
Alexion to Present at the Virtual Bank of America Securities 2020 Healthcare Conference on Tuesday, May 12th
Release Versions
English

Contacts

Investors
Chris Stevo
Head of Investor Relations
(857) 338-9309

More News From Alexion Pharmaceuticals

Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

BOSTON--(BUSINESS WIRE)--Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)....

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the EHA Congress 2021...

 Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

BOSTON--(BUSINESS WIRE)--Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)...
Back to Newsroom